Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (16671)
All Articles published online
|
Publishing Process of This Article
|
Nov 28, 2022 (publication date) through May 23, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28(44): 6294-6309 [PMID: 36504556 DOI: 10.3748/wjg.v28.i44.6294] |
|
|
|
| All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply. | |
| For: | Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28(44): 6294-6309 [PMID: 36504556 DOI: 10.3748/wjg.v28.i44.6294] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i44/6294.htm |
| Number | Citing Articles |
| 1 |
Shin Yeong Kim, Hankil Lee, Jong Seung Kim, Jae Hyun Kim, Ha-Lim Jeon. Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD. Kidney International Reports 2026; 11(6): 106524 doi: 10.1016/j.ekir.2026.106524
|
| 2 |
Amit Patel, Loren Laine, Paul Moayyedi, Justin Wu. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 2024; 167(6): 1228 doi: 10.1053/j.gastro.2024.06.038
|
| 3 |
Siying Zhu, Muzhou Han, Ye Zong, Fandong Meng, Qi Liu, Biguang Tuo, Zhenyu Zhang, Qizhi Wang, Xiaowei Liu, Song He, Yanbo Zhen, Dong Shao, Shenglan Wang, Baohong Xu, Xing Li, Haitao Tang, Yangde Miu, Chengxia Liu, Jiuye Hu, Pingsheng Hu, Jin Xiu, Ming Lu, Yongdong Wu, Shutian Zhang. A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis. Clinical and Translational Gastroenterology 2025; 16(4): e00803 doi: 10.14309/ctg.0000000000000803
|
| 4 |
Sang Pyo Lee, In-Kyung Sung, Oh Young Lee, Myung-Gyu Choi, Kyu Chan Huh, Jae-Young Jang, Hoon Jai Chun, Joong-Goo Kwon, Gwang Ha Kim, Nayoung Kim, Poong-Lyul Rhee, Sang Gyun Kim, Hwoon-Yong Jung, Joon Seong Lee, Yong Chan Lee, Hye-Kyung Jung, Jae Gyu Kim, Sung Kook Kim, Chong-il Sohn. Randomized Multicenter Study to Evaluate the Efficacy and Safety of Fexuprazan According to the Timing of Dosing in Patients With Erosive Esophagitis. Journal of Neurogastroenterology and Motility 2025; 31(1): 86 doi: 10.5056/jnm24032
|
| 5 |
Wonsuk Shin, A-Young Yang, Hyung Park, Hyejung Lee, Hyounggyoon Yoo, Anhye Kim. A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State. Pharmaceuticals 2023; 16(8): 1141 doi: 10.3390/ph16081141
|
| 6 |
Sowmya Errabaka, Haritha Pasupulati, Satyanarayana SV Padi. PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases. International Journal of Health Sciences and Research 2026; : 109 doi: 10.52403/ijhsr.20260215
|
| 7 |
M.A. Valdovinos-Díaz, A. Hani, C. Defilippi-Guerra, L. Fernando-Pineda, J.M. Remes-Troche, A. Riquelme, L.J. Abrahão-Junior, L. Aguilar-Paiz, C. Almonte-Nuñez, H. Burgos, C. Días, O. Gómez-Escudero, I. Hanna-Jairala, C. Olano, J.A. Olmos, A. Ortiz, G. Otoya, J.L. Tamayo-de la Cuesta, J. Suazo-Barahona, E. Vesco-Monteagudo, L.R. Valdovinos-García, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica para el manejo de la enfermedad por reflujo gastroesofágico. Revisión por expertos latinoamericanos. Revista de Gastroenterología de México 2025; 90(2): 288 doi: 10.1016/j.rgmx.2025.02.001
|
| 8 |
Kyoung A Ko, Dong-Kyu Lee. Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2025; 25(1): 34 doi: 10.7704/kjhugr.2025.0004
|
| 9 |
Jin Won Chang, Da Hyun Jung, Nak-Hoon Son, Sohyeon Gwon, Da Mi Jeong, Cheal Wung Huh. Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Network Meta-analysis. Journal of Neurogastroenterology and Motility 2026; 32(2): 172 doi: 10.5056/jnm25161
|
| 10 |
Azaan Ramani, Alisha Merchant, Brooks D. Cash. Review of the clinical development of fexuprazan for gastroesophageal reflux–related disease. European Journal of Clinical Pharmacology 2023; 79(8): 1023 doi: 10.1007/s00228-023-03521-4
|
| 11 |
Dong Jun Oh, Dong Hwan Park, Jiyun Jung, Yun Jeong Lim. Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study. Journal of Neurogastroenterology and Motility 2026; 32(1): 52 doi: 10.5056/jnm25119
|
| 12 |
Thai Hau Koo, Ronnie Fass. A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease. Esophagus 2026; 23(2): 275 doi: 10.1007/s10388-025-01181-0
|
| 13 |
Daniel Martin Simadibrata, Elvira Lesmana, Yeong Yeh Lee. Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?. Expert Opinion on Investigational Drugs 2024; 33(10): 1009 doi: 10.1080/13543784.2024.2393868
|
| 14 |
Byeong Yun Ahn, Soo-Jeong Cho. Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 174 doi: 10.7704/kjhugr.2023.0041
|
| 15 |
Seungyeon Seo, Hye-Kyung Jung, C Prakash Gyawali, Hye Ah Lee, Hyung Seok Lim, Eui Sun Jeong, Seong Eun Kim, Chang Mo Moon. Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis. Journal of Neurogastroenterology and Motility 2024; 30(3): 259 doi: 10.5056/jnm24024
|
| 16 |
Jiten P. Kothadia, Colin W. Howden. Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease. Foregut: The Journal of the American Foregut Society 2024; 4(1): 7 doi: 10.1177/26345161231181357
|
| 17 |
Jung-Hwan Oh, Hyun-Soo Kim, Dae Young Cheung, Hang Lak Lee, Dong Ho Lee, Gwang Ha Kim, Suck Chei Choi, Yu Kyung Cho, Woo Chul Chung, Ji Won Kim, Eunju Yu, Hyesoo Kwon, Jun Kim, John Kim, Hwoon-Yong Jung. Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis. American Journal of Gastroenterology 2025; 120(2): 353 doi: 10.14309/ajg.0000000000002929
|
| 18 |
In Mo Yoon, Kang-Yon Kim, Kwan-Haeng Lee, Duk-Woo Yoo, Hojin Oh. Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System. Current Therapeutic Research 2025; 102: 100776 doi: 10.1016/j.curtheres.2025.100776
|
| 19 |
Elisa Marabotto, Francesco Calabrese, Andrea Pasta, Pierfrancesco Visaggi, Nicola de Bortoli, Amir Mari, Salvatore Tolone, Matteo Ghisa, Luisa Bertin, Vincenzo Savarino, Edoardo Vincenzo Savarino. Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults. Expert Opinion on Pharmacotherapy 2024; 25(17): 2319 doi: 10.1080/14656566.2024.2427335
|
| 20 |
Qianjun Zhuang, Aijun Liao, Qingling He, Chengxia Liu, Changqing Zheng, Xing Li, Youli Liu, Bangmao Wang, Side Liu, Yan Zhang, Rong Lin, Huixin Chen, Min Deng, Yanping Tang, Chiyi He, Weijie Dai, Haitao Tang, Lei Gong, Liangping Li, Baohong Xu, Changqing Yang, Bingxi Zhou, Dongxing Su, Qinghong Guo, Bin Li, Yongjian Zhou, Xiaoyang Wang, Sujuan Fei, Huili Wu, Sichen Wei, Zhihong Peng, Jianning Wang, Yanqing Li, Hong Wang, Tianwei Deng, Shigang Ding, Fangfang Li, Minhu Chen, Yinglian Xiao. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study. Journal of Gastroenterology and Hepatology 2024; 39(4): 658 doi: 10.1111/jgh.16471
|
| 21 |
Saba Ahmed, Saad Asghar, Maryam Khanzada, Fnu Soxi, Hamesh Gundala Raja, Mehak Gul, Muhammad M Tariq, Momina Abid, Fazal Carpenter. Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review. Cureus 2025; doi: 10.7759/cureus.84311
|
| 22 |
Tae Lyn Kim, Jinyeong Jeon, Cheol-Hong Cheon. Total Synthesis of Fexuprazan. Organic Letters 2026; 28(14): 4421 doi: 10.1021/acs.orglett.6c00563
|
| 23 |
Su Il Kim, Young Chan Lee, Wonjae Cha, Ah Ra Jung, Jeon Yeob Jang, Jeong-Seok Choi, Dong Kun Lee, Hwan Ho Lee, Min Su Kwon, Yoon Se Lee, Young-Gyu Eun. Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial. European Archives of Oto-Rhino-Laryngology 2024; 281(11): 5873 doi: 10.1007/s00405-024-08877-6
|
| 24 |
Mohammad Al Hayek, Alfredo J. Lucendo, Brigida Barberio, Rena Yadlapati, Mohamedhen Vall Nounou, Mohammed S. Beshr, C. Prakash Gyawali, Walter W. Chan, Abdelaziz H. Salama, Muhammed Elhadi, Edoardo Vincenzo Savarino, Loren Laine. Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials. eClinicalMedicine 2026; 93: 103807 doi: 10.1016/j.eclinm.2026.103807
|
| 25 |
Yong Sung Kim, Hyun Lim, Boram Cha, Seung Han Kim, Da Hyun Jung, Su Jin Kim, Suck Chei Choi. From Trials to Practice: Exploring the Clinical Value of Potassium-competitive Acid Blockers. Journal of Neurogastroenterology and Motility 2025; 31(3): 401 doi: 10.5056/jnm25099
|
| 26 |
M.A. Valdovinos-Díaz, A. Hani, C. Defilippi-Guerra, L. Fernando-Pineda, J.M. Remes-Troche, A. Riquelme, L.J. Abrahão-Junior, L. Aguilar-Paiz, C. Almonte-Nuñez, H. Burgos, C. Días, O. Gómez-Escudero, I. Hanna-Jairala, C. Olano, J.A. Olmos, A. Ortiz, G. Otoya, J.L. Tamayo-de la Cuesta, J. Suazo-Barahona, E. Vesco-Monteagudo, L.R. Valdovinos-García, J.S. Arenas-Martínez. Good clinical practice recommendations for the management of gastroesophageal reflux disease. A Latin American expert review. Revista de Gastroenterología de México (English Edition) 2025; 90(2): 288 doi: 10.1016/j.rgmxen.2025.02.001
|
| 27 |
William A. Barzola-Farfán, Carlos Quispe-Vicuña, Oriana Rivera-Lozada, Cesar Bonilla-Asalde, Joshuan J. Barboza. Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2026; 15(4): 1434 doi: 10.3390/jcm15041434
|
| 28 |
Stuart Spechler, Jennifer M. Kolb, Kerry Dunbar, C. Prakash Gyawali, Reginald Bell, Ronnie Fass, Philip Katz, Loren Laine, John Lipham, Felice Schnoll-Sussman, Rhonda F. Souza, Rena Yadlapati, Peter J. Kahrilas. American Foregut Society White Paper Report on the Use of Potassium-Competitive Acid Blockers in the Treatment of Gastroesophageal Reflux Disease. Foregut: The Journal of the American Foregut Society 2025; 5(3): 195 doi: 10.1177/26345161251325874
|
| 29 |
Feihan Li, Jiawu Tan, Lifeng Qin. Efficacy, safety and cost-effectiveness of potassium-competitive acid blockers versus proton pump inhibitors in gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology 2026; 61(2): 241 doi: 10.1080/00365521.2025.2603613
|
| 30 |
Yuan Fang, Xia He, Ai Peng, Yi qi Yang, Jin Xiang. Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms. Clinical Pharmacology in Drug Development 2024; 13(2): 134 doi: 10.1002/cpdd.1334
|
| 31 |
Inyoung Hwang, SeungHwan Lee. Editorial: deja vu all over again – let the P‐CAB wars begin. Authors' reply. Alimentary Pharmacology & Therapeutics 2023; 57(8): 914 doi: 10.1111/apt.17444
|
| 32 |
Yin Liu, Zhifeng Gao, XiaoHua Hou. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241251567
|
| 33 |
Yingying Fang, Dandi Lou, Jie Zhou, Qiufeng Zhang, Youran Dai, Wei Ren. Efficacy and Safety of Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors in Treating Erosive Esophagitis. Journal of Clinical Gastroenterology 2024; 58(9): 841 doi: 10.1097/MCG.0000000000002052
|
| 34 |
Demeke E Agago , Najma Hanif, Ariga Sai Ajay Kumar, Muhammad Arsalan, Manpreet Kaur Dhanjal , Lubna Hanif, Calvin R Wei. Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024; doi: 10.7759/cureus.65141
|
| 35 |
Min Seo Lee, Jihoon Lee, Minyoung Pang, John Kim, Hyunju Cha, Banyoon Cheon, Min-Koo Choi, Im-Sook Song, Hye Suk Lee. In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics 2024; 16(6): 799 doi: 10.3390/pharmaceutics16060799
|
| 36 |
Dong Han Yeom, Yong Sung Kim. History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 159 doi: 10.7704/kjhugr.2023.0040
|
| 37 |
E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of use. Experimental and Clinical Gastroenterology 2023; (4): 86 doi: 10.31146/1682-8658-ecg-212-4-86-92
|
| 38 |
Yewon Jang, Jongho Park, Dahee Kang, Jae Hyun Kim, Hyuk Soon Choi, Ha‐Lim Jeon, Hankil Lee. Safety of Potassium‐Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta‐Analysis. Journal of Gastroenterology and Hepatology 2026; 41(1): 28 doi: 10.1111/jgh.70178
|
| 39 |
Noy Lapidot Alon, Richard Wong, Tomas Navarro-Rodriguez, Raúl Alberto Jiménez-Castillo, Ronnie Fass. Future Opportunities for Potassium Competitive Acid Blocker in Gastroesophageal Reflux Disease and Beyond. Foregut: The Journal of the American Foregut Society 2026; 6(1): 3 doi: 10.1177/26345161251389192
|
| 40 |
Minyoul Baik, Jeong A. Shin, Joonsang Yoo, Jinkwon Kim, Devesh U Kapoor. Fexuprazan for upper gastrointestinal protection in patients with ischemic stroke and gastroesophageal reflux disease (GERD) receiving antithrombotic therapy: A preliminary prospective single-arm observational Study. PLOS One 2026; 21(4): e0346145 doi: 10.1371/journal.pone.0346145
|
| 41 |
Noeul Kang, Min-Gyu Kang, Seung Eun Lee, Sung-Yoon Kang, Eun-Jung Jo, Ji Ho Lee, Sae-Hoon Kim, Joon-Woo Bahn, Byung-Jae Lee, Woo-Jung Song. Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. Lung 2025; 203(1) doi: 10.1007/s00408-025-00815-5
|
| 42 |
Xinwei Qiao, Peng Li. Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review. Frontiers in Physiology 2025; 16 doi: 10.3389/fphys.2025.1655102
|
| 43 |
Jong Kyu Park. Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 180 doi: 10.7704/kjhugr.2023.0034
|
| 44 |
Ah Young Yoo, Moon Kyung Joo, Jong-Jae Park, Beom Jae Lee, Seung Han Kim, Won Shik Kim, Hoon Jai Chun. Recurrent Non-Variceal Upper Gastrointestinal Bleeding among Patients Receiving Dual Antiplatelet Therapy. Diagnostics 2023; 13(22): 3444 doi: 10.3390/diagnostics13223444
|
| 45 |
Erika Araujo, Ian M. Bell, Alexander Burckle, Dennis C. Koester, James R. Manning, Georgette Castanedo, Mingshuo Zeng, T. G. Murali Dhar, Natalie Holmberg-Douglas, Eric R. Welin, J. Robert Merritt, Kevin M. Peese, Joanne J. Bronson. 2023 Medicinal Chemistry Reviews. Medicinal Chemistry Reviews 2023; 58: 595 doi: 10.1021/mc-2023-vol58.ch24
|
| 46 |
Trevor A. Davis, C. Prakash Gyawali. Potassium-competitive acid blockers. Current Opinion in Gastroenterology 2025; 41(6): 389 doi: 10.1097/MOG.0000000000001127
|
| 47 |
Ji-Hyeon Jeon, Jihoon Lee, Yeon-Ju Baek, Kwon-Jo Lim, Ji Duck Kim, Joon Seok Park, Min-Koo Choi, Im-Sook Song. Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats. Biomedicine & Pharmacotherapy 2025; 188: 118185 doi: 10.1016/j.biopha.2025.118185
|
| 48 |
Mun Young Cho, Yu Kyung Cho. Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(3): 167 doi: 10.7704/kjhugr.2023.0043
|
| 49 |
Hideki Mori, Hidekazu Suzuki. Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression. Journal of Gastroenterology 2026; doi: 10.1007/s00535-026-02422-4
|
| 50 |
Byung Wook Jung, Chan Hyuk Park, Chang Soo Eun. Preference for On-Demand Fexuprazan Therapy in Gastroesophageal Reflux Disease: A Prospective Cohort Study. Journal of Personalized Medicine 2025; 15(1): 19 doi: 10.3390/jpm15010019
|
| 51 |
Xinxu Zhou, Hui Duan, Qian Li, Qiong Wang, Xiaobin Sun. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 2024; 59(7): 788 doi: 10.1080/00365521.2024.2349638
|
| 52 |
Yuchul Jeong, Beom Jun Lee, Se-Hyeon Han. RETRACTED: Jeong et al. A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis. J. Clin. Med. 2024, 13, 3262. Journal of Clinical Medicine 2024; 13(21): 6388 doi: 10.3390/jcm13216388
|
| 53 |
Seo Yeon Kim, Jung-Ho Yoon, Da Hyun Jung, Ga Hee Kim, Chul Hoon Kim, Sang Kil Lee. RETRACTED: Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1410904
|
| 54 |
Yujiao Wang, Xiaosong Dai, Xinxing Zhang. Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders. Clinical and Translational Gastroenterology 2024; 15(11): e00776 doi: 10.14309/ctg.0000000000000776
|
| 55 |
Ting Wang, Yueting Hua, Fangbo Deng, Rui Wen, Haoyu Zhang, Chunshi Li, Yang Liu, Maosheng Cheng. Scalable Synthesis of the Key Fexuprazan Intermediate and Investigation of a Reaction Mechanism. ACS Omega 2024; 9(36): 37942 doi: 10.1021/acsomega.4c04507
|